{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 40 of 122', '5.5.1', 'Safety Follow-Up for Subjects With GI Adverse Events of Interest', 'For subjects who had GI adverse events of interest (ie, with prolonged dose interruption or', 'that result in or are ongoing at early discontinuation; Section 8.5.6.2), parents/caregivers and', 'subjects aged > 8 years will complete the Pediatric Eosinophilic Esophagitis Symptom', 'Scores version 2.0 (PEESS v2.0) questionnaire while the subject is symptomatic, at early', 'discontinuation or study exit, and monthly for 6 months.', 'In addition, subjects who discontinue early due to GI adverse events will return to the study', 'site monthly for at least 6 months; telephone follow-up by medically qualified personnel may', 'be appropriate in the absence of symptoms, at the discretion of the investigator.', 'A gastroenterologist referral should be initiated for subjects with GI adverse events persisting', '> 6 weeks after early treatment discontinuation, and for subjects unable to discontinue using', 'therapies initiated for GI symptoms (eg, H1 or H2 histamine blockers, proton pump', 'inhibitors) by 12 weeks after early treatment discontinuation. Gastroenterologist visits, test', 'results, and endoscopy and endoscopic biopsy results (if applicable) will be documented in', \"the subject's source documents.\", 'Follow-up will continue for chronic or recurrent GI symptoms persisting after 6 months until', 'symptoms resolve or stabilize.', '5.6 Loss to Follow-Up', 'Every reasonable effort must be made to contact any subject apparently lost to follow-up', 'during the study to complete study-related assessments and record outstanding data. After', 'unsuccessful telephone contact, the following is to occur:', 'Attempt to contact the subject by mail using a method that provides proof of receipt.', 'Try alternate contacts if permitted (eg, primary care providers, referring physician,', 'relatives).', \"Document the efforts in the subject's source documents.\", 'If all efforts fail to establish contact, the subject will be considered lost to follow-up.', '6', 'INVESTIGATIONAL PRODUCT INFORMATION', '6.1', 'General Information', 'The study treatments include AR101 and standard of care. Standard of care includes', 'avoidance of peanuts/peanut-containing foods, and education on recognition and', 'management of allergy symptoms and appropriate use of rescue medications (eg, epinephrine', 'auto-injectors).', 'The sponsor will provide AR101 capsules and sachets.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 41 of 122', '6.2 AR101 Product Characteristics', 'The AR101 active pharmaceutical ingredient is initially sourced as raw peanuts, Arachis', 'hypogaea, and is processed into food-grade, 12% defatted, roasted peanut flour that contains', 'approximately 50% peanut protein (wt/wt). The peanut flour, which contains peanut', 'allergens, is characterized for its relative composition of key allergenic proteins', '(Porterfield, 2009) by reversed-phase high performance liquid chromatography (HPLC) and', 'is tested for potency (relative to a reference standard) using an enzyme-linked', 'immunosorbent assay (ELISA) to demonstrate consistency between lots. The AR101 drug', 'product consists of the peanut flour formulated with bulking and flow agents in graduated', 'doses. The drug product is encapsulated in hydroxypropyl methyl cellulose (HPMC) or filled', 'in foil-laminate sachets and supplied in color-coded pull-apart capsules at 5 dosage strengths', '(0.5, 1, 10, 20, and 100 mg) and 300 mg sachets.', 'Additional details will be provided in the AR101 investigator brochure and pharmacy', 'manual.', '6.2.1', 'Packaging of AR101', 'Capsules containing study product are packaged in blister cards that are assembled into', 'dosing kits. Each individual blister of a blister card contains a dose for a single day. Each', 'dosing kit supplies 2 weeks of daily dosing for a single dose level plus another 7 days of', 'daily dosing at the same dose level to accommodate potential visit scheduling issues and', 'wasted or lost product.', 'Foil-laminate sachets for maintenance dosing are packaged in paperboard cartons for storage', 'and dispensing to study subjects.', 'The label will vary depending on individual country requirements.', '6.2.2', 'Storage of AR101', 'The study product should be stored in accordance with the product label and in a secure', 'location at 2\u00b0C to 8\u00b0C. Temperature excursions may be allowed with specific instructions', 'from Aimmune. Study sites will maintain temperature logs for all refrigerators used to store', 'study product during the study.', '6.2.3 Directions for Administration of AR101', 'The first dose at each dose level will be removed from the dosing kit for the assigned dose', 'level and administered under medical supervision at the study site. Once a dose is removed', 'from the dosing kit, the kit must be dispensed to the subject, held at the study site for', 'destruction, or returned to the sponsor designee according to the procedures in the pharmacy', 'manual. Once opened, dosing kits cannot be used for any other dosing interval or any other', 'subject. Subjects will be instructed to store the dosing kit in the refrigerator and return', 'unused study product to the study site at the next visit.']\n\n###\n\n", "completion": "END"}